StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock.
Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 target price on shares of OncoCyte in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $4.06.
View Our Latest Stock Report on OCX
OncoCyte Price Performance
OncoCyte (NASDAQ:OCX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.
OncoCyte Company Profile
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Further Reading
- Five stocks we like better than OncoCyte
- What Are Dividend Achievers? An Introduction
- Visa and Mastercard: Top Payment Stocks to Watch After Rate Cuts
- What is Forex and How Does it Work?
- When Is the Best Time to Invest in Mutual Funds?
- How to Calculate Inflation Rate
- Is NVIDIA Stock in a Correction or Consolidation?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.